CN104736521A - 瑞格非尼盐晶型及其制备方法和用途 - Google Patents

瑞格非尼盐晶型及其制备方法和用途 Download PDF

Info

Publication number
CN104736521A
CN104736521A CN201380052962.5A CN201380052962A CN104736521A CN 104736521 A CN104736521 A CN 104736521A CN 201380052962 A CN201380052962 A CN 201380052962A CN 104736521 A CN104736521 A CN 104736521A
Authority
CN
China
Prior art keywords
scholars
rui gefeini
scholar
crystal formation
rui
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380052962.5A
Other languages
English (en)
Other versions
CN104736521B (zh
Inventor
宋小叶
劳海萍
盛晓霞
盛晓红
Original Assignee
Hangzhou Pushai Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Pushai Pharmaceutical Technology Co ltd filed Critical Hangzhou Pushai Pharmaceutical Technology Co ltd
Publication of CN104736521A publication Critical patent/CN104736521A/zh
Application granted granted Critical
Publication of CN104736521B publication Critical patent/CN104736521B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本申请涉及新型的瑞格非尼盐及其晶型，与已知的瑞格非尼一水合物及其晶型相比，本申请的瑞格非尼盐及其晶型具有一种或多种改进的特性。本申请还涉及所述瑞格非尼盐及其晶型的制备方法、其药物组合物、及其用于制备治疗转移性结肠直肠癌的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201380052962.5A 2013-09-12 2013-09-12 瑞格非尼盐晶型及其制备方法和用途 Active CN104736521B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/001056 WO2015035531A1 (zh) 2013-09-12 2013-09-12 瑞格非尼盐晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN104736521A true CN104736521A (zh) 2015-06-24
CN104736521B CN104736521B (zh) 2016-10-12

Family

ID=52664894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380052962.5A Active CN104736521B (zh) 2013-09-12 2013-09-12 瑞格非尼盐晶型及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN104736521B (zh)
WO (1) WO2015035531A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856469A (zh) * 2003-07-23 2006-11-01 拜尔医药品股份有限公司 用于治疗和预防疾病和疾病症状的氟代ω－羧芳基二苯基脲
WO2011113366A1 (zh) * 2010-03-18 2011-09-22 苏州泽璟生物制药有限公司 制备氘代二苯基脲的方法
WO2012012404A1 (en) * 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CN103079567A (zh) * 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856469A (zh) * 2003-07-23 2006-11-01 拜尔医药品股份有限公司 用于治疗和预防疾病和疾病症状的氟代ω－羧芳基二苯基脲
WO2011113366A1 (zh) * 2010-03-18 2011-09-22 苏州泽璟生物制药有限公司 制备氘代二苯基脲的方法
CN103079567A (zh) * 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
WO2012012404A1 (en) * 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Also Published As

Publication number Publication date
WO2015035531A1 (zh) 2015-03-19
CN104736521B (zh) 2016-10-12

Similar Documents

Publication Publication Date Title
CN105188699B (zh) 恩杂鲁胺的固态形式及其制备方法和用途
CN105073740B (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CN104736526A (zh) 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
CN105693624B (zh) 马西替坦晶体及其制备方法、其药物组合物和用途
CN104284897A (zh) 替卡格雷晶型及其制备方法和用途
CN104736538A (zh) 一种抑制剂的晶型及其制备方法和用途
CN106866701A (zh) 德罗格韦钠盐的晶型及其制备方法
CN110156700A (zh) 吉非替尼与水杨酸共晶体
CN108137504A (zh) 肌醇烟酸酯晶型a及其制备方法
CN104918937A (zh) 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
US9708301B2 (en) Crystalline forms of afatinib monomaleate, preparation methods and pharmaceutical compositions thereof
JP7295025B2 (ja) （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態
CN104540822A (zh) 达拉菲尼甲磺酸盐的新晶型及其制备方法
WO2014036865A1 (zh) 芬戈莫德粘酸盐及其晶体的制备方法和用途
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN108239055A (zh) 一种thr1442 l-天冬氨酸共晶、其制备方法及药物组合物
CN103421011A (zh) 一种制备磷酸西他列汀无水晶型i的方法
CN112778290B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
CN109438370A (zh) 一种甲基吡嗪衍生物无水晶型
CN104736521A (zh) 瑞格非尼盐晶型及其制备方法和用途
CN105315266B (zh) 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN104379581B (zh) 达拉菲尼的晶型及其制备方法和用途
CN106928228A (zh) 奥格列汀盐及其晶型、它们的制备方法和药物组合物
CN104936947A (zh) 氯卡色林盐及其晶体、其制备方法和用途
CN105308043B (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20191015

Address after: 318000 room 3-1-202, Tengda new village, Jiaojiang District, Taizhou City, Zhejiang Province

Patentee after: Ni Yun

Address before: 310018 room 2B12, building 452, No. 6, Hangzhou Economic & Technological Development Zone, Hangzhou, Zhejiang, China

Patentee before: HANGZHOU PUSHA PHARMACEUTICAL TECHNOLOGY CO., LTD.